Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial
2016 ESMO Congress
Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Abstract LBA43)
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)